Life-Threatening Reaction to Lifesaving Medication

Tia Bimal; Anthony Szema; Maia Pavlovic; Dean Karalis; Eugenia Gianos

doi:10.1016/j.jaccas.2024.102614

Back

Life-Threatening Reaction to Lifesaving Medication

Journal article

Open access

Peer reviewed

Life-Threatening Reaction to Lifesaving Medication

Tia Bimal, Anthony Szema, Maia Pavlovic, Dean Karalis and Eugenia Gianos

JACC. Case reports, v 29(19), 102614

02 Oct 2024

DOI: https://doi.org/10.1016/j.jaccas.2024.102614

Files and links (1)

url

https://doi.org/10.1016/j.jaccas.2024.102614View

Published, Version of Record (VoR) Open

Abstract

biotechnology

cardiovascular disease

complication

hypercholesterolemia

inherited metabolic disorders

lipid metabolism disorders

pericardial effusion

pleural effusion

treatment

Typical side effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies including influenza-like illness and injection site reactions, are minor and well tolerated. This case, however, highlights a less common but severe reaction, indicating the need for clinicians to understand and manage potential rare side effects noted with biologics. [Display omitted]

Metrics

21 Record Views

See more details

Details

Title: Life-Threatening Reaction to Lifesaving Medication
Creators: Tia Bimal - Lenox Hill Hospital
Anthony Szema - Northwell Health
Maia Pavlovic - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA
Dean Karalis - Thomas Jefferson University Hospital
Eugenia Gianos - Lenox Hill Hospital
Publication Details: JACC. Case reports, v 29(19), 102614
Publisher: Elsevier
Resource Type: Journal article
Language: English
Academic Unit: College of Medicine
Scopus ID: 2-s2.0-85204476646
Other Identifier: 991021906215704721

Life-Threatening Reaction to Lifesaving Medication

Files and links (1)

Abstract

Metrics

Details

Drexel University Social media